No Irish bar for Teva on Mylan glatiramer
Teva has been refused by Ireland’s High Court an injunction to stop Mylan producing its US rival to Copaxone (glatiramer acetate) 40mg/ml at a local facility in Inverin, County Galway. The Israeli firm had claimed that Mylan’s production of the generic version of the multiple-sclerosis brand infringed the Irish counterpart of European patent EP2,949,335, titled ‘low frequency glatiramer acetate therapy’.
You may also be interested in...
Mylan has celebrated a reversal from the European Patent Office that has seen a key patent protecting Teva’s higher-strength 40mg/ml thrice-weekly version of Copaxone deemed invalid and revoked across Europe. Meanwhile, Teva has commented on the possibility of an appeal.
Teva has won a victory in persuading the European Patent Office to uphold a Copaxone dosing patent that it had granted. But national courts may take a different view on validity.
A new paper has examined the issue of biosimilar-to-biosimilar switching, concluding that it is a safe and effective clinical practice but highlighting a lack of current health authority regulations or guidance on the subject.